Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL27499862 | 0.97 | ALDH1A1 (0.47) | ALDH1A1FFAR3LCKFYNCA2 | |
| Piperidine SCHEMBL10332243 | 0.97 | ALDH1A1 (0.56) | ALDH1A1FFAR3LCKFYNCA2 | |
| Piperidine SCHEMBL29043025 | 0.97 | ALDH1A1 (0.56) | ALDH1A1FFAR3LCKFYNCA2 | |
| Piperidine SCHEMBL192668 | 0.97 | ALDH1A1 (0.56) | ALDH1A1FFAR3LCKFYNCA2 | |
| Pyrrolidine SCHEMBL2797002 | 0.94 | — | — | |
| Piperidine SCHEMBL10969397 | 0.92 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNCA2 | |
| Piperidine SCHEMBL15571721 | 0.92 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNCA2 | |
| Piperidine SCHEMBL15571381 | 0.92 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNCA2 | |
| Piperidine SCHEMBL27769626 | 0.91 | ALDH1A1 (0.56) | ALDH1A1CA2CHKASMN1; SMN2CXCR4 | |
| Acetic Acid SCHEMBL29130314 | 0.91 | SMN1; SMN2 (0.47) | ALDH1A1FFAR3LCKFYNCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| CN-101437816-A | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC (US) | 2009-05-20 | — | — | CN | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | ALDH1A1 77/4885FFAR3 485/4885LCK 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.